Feature|Videos|July 16, 2025
Designing Effective Value-Based Contracts: Timing, Evidence, and Risk Alignment
Industry experts react to the developer’s role in preparing for value-based contracting, acknowledging that innovative agreements can support access when evidence is still maturing.
Advertisement
Episodes in this series
There is no shortcut to executing a value-based contract. In this episode, experts lay out what’s required to bring these agreements to life: evidence alignment, data compatibility, and mutual incentive. Payers want results, not just risk transference—and developers must understand and speak to payer business goals.
Key discussion topics include:
- Timeline and prerequisites for executing value-based contracts.
- Understanding what matters to payers vs. regulators.
- How to prototype contracting models for early feedback.
- The importance of strong head-to-head clinical data as the foundation.
Advertisement
Related to this article
Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.
Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.
Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.
Accessia Health’s Tiara Green says Part D reforms eased drug costs, but premiums, deductibles and payer policies still limit patient access.
ELPRO CEO Frederik Dresen explains how cold chain monitoring moved from compliance to risk management, and what biologics and advanced therapies demand.
Inizio Ignite leaders argue static, milestone-driven launch plans fall short and AI sharpens execution only when built on a sound strategy.
Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: CVS Health to Break in Two, Bayer Weighs MFN
2
2026 Brought Progress on Drug Prices. What Will It Take to Improve Patient Access in 2027?
3
Big Three Distributors Lean on Specialty for Profit Growth
4
The System-Level View That Sound Market Access Decisions Are Missing
5